Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) has announced the acquisition of Resilient Cosmeceuticals Private Limited’s India business for ₹24 crore. The deal, funded through internal accruals, will be completed within 45 days, subject to customary closing conditions. As of December 31, 2024, Jagsonpal had a strong cash reserve of ₹132 crore, reinforcing its financial capability for strategic expansions.
This acquisition aligns with Jagsonpal’s vision of strengthening its presence in key therapeutic segments. By adding a complementary portfolio of pharmaceuticals, nutritional, and cosmetic products, the company is tapping into a ₹1000 crore market opportunity in India. The deal enhances Jagsonpal’s leadership in gynaecology while expanding its footprint in dermatology, particularly in high-growth segments such as acne, hair care, and moisturizers.
With a well-established wellness brand now under its umbrella, Jagsonpal gains a competitive edge in India’s high-value regions, including Maharashtra, Karnataka, and Kerala. The transaction also enhances engagement with specialist doctors, particularly dermatologists and gynaecologists, fostering deeper market penetration.
Commenting on the acquisition, Manish Gupta, Managing Director of Jagsonpal Pharmaceuticals, stated, “This acquisition is a strategic move in Jagsonpal’s growth journey, reinforcing our commitment to scaling operations and enhancing our market presence in our focus therapies, leveraging the surplus cash generated from operations. The acquired business is complementary to Jagsonpal’s existing portfolio, and we are confident that it will deliver long-term value to all stakeholders.”
